Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jan 27;11(1):531.
doi: 10.1038/s41467-020-14392-z.

Overcoming MCL-1-driven adaptive resistance to targeted therapies

Kris C Wood  1
Affiliations
Comment

Overcoming MCL-1-driven adaptive resistance to targeted therapies

Kris C Wood. Nat Commun. .

Abstract

Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Comment on

References

    1. Bivona TG, Doebele RC. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 2016;22:472–478. doi: 10.1038/nm.4091. - DOI - PMC - PubMed
    1. Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015;5:475–487. doi: 10.1158/2159-8290.CD-15-0011. - DOI - PMC - PubMed
    1. Soderquist RS, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat. Commun. 2018;9:3513. doi: 10.1038/s41467-018-05815-z. - DOI - PMC - PubMed
    1. Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 2015;7:279ra240. doi: 10.1126/scitranslmed.aaa4642. - DOI - PubMed
    1. Kotschy A, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477–482. doi: 10.1038/nature19830. - DOI - PubMed

Substances